GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law FirmPRNewsWire • 07/16/25
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025Business Wire • 07/14/25
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 MillionBenzinga • 07/09/25
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a BetZacks Investment Research • 07/09/25
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income CountriesBusiness Wire • 07/09/25
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?Zacks Investment Research • 07/08/25
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than othersCNBC • 07/08/25
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 07/08/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILDGlobeNewsWire • 07/06/25
Why This Looming Supreme Court Decision Could Rattle Gilead SciencesInvestors Business Daily • 06/27/25
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 DegradersBusiness Wire • 06/25/25
Gilead's twice-yearly PrEP injection wins FDA approval, analysts see solid launch aheadProactive Investors • 06/18/25